Fallacy Alarm

Fallacy Alarm

Share this post

Fallacy Alarm
Fallacy Alarm
My template for trading Biotech stocks

My template for trading Biotech stocks

Results of clinical trials can be existential for pre-revenue companies. Here is how I trade that with options.

Rene Bruentrup's avatar
Rene Bruentrup
Jan 01, 2024
∙ Paid
13

Share this post

Fallacy Alarm
Fallacy Alarm
My template for trading Biotech stocks
8
1
Share

Disclaimer: The information contained in this article is not and should not be construed as investment advice. This is my investing journey and I simply share what I do and why I do that for educational and entertainment purposes.


To understand what follows, it will be helpful if you have studied options and performed research on the biotech sector before, but it is not required. You simply need an open mind and a healthy amount of curiosity. It would also be beneficial if you familiarize yourself with my previous work on derivatives. This article does not directly build on those linked below, but they are helpful context to understand how I think about convexity and volatility.

Liquidity Provision Risk Premium and the Cost of Leverage

Liquidity Provision Risk Premium and the Cost of Leverage

Fallacy Alarm
·
March 25, 2023
Read full story
Shorting UVXY: Madness or Money Maker?

Shorting UVXY: Madness or Money Maker?

Fallacy Alarm
·
July 25, 2023
Read full story
The Great Pandemic Era Option Bubble

The Great Pandemic Era Option Bubble

Fallacy Alarm
·
February 12, 2023
Read full story

Fallacy Alarm is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.


I haven’t told you before, but I actually spent the first years of my career assisting portfolio managers in a mutual fund company as a research associate. One of them ran the firm’s healthcare and biotechnology products. It was a mysterious, but fascinating world that seemed to be detached from anything else in the markets. My main task was to build and maintain the financial models for the funds’ holdings, which involved running risk-adjusted NPV calculations for compounds in clinical trials. I did this with the help of sellside research analysts because it’s a challenging task, particularly for a science outsider like me. You need a good handle on the market opportunity and how the drug candidate fits in.

When an important clinical trial came to its conclusion or reached an important milestone, investors got very nervous and excited. This was nowhere as visible as in the option chain which got incredibly juicy. I remember very well how grumpy my boss got when he wanted to place a directional bet based on our research only to realize that the options were priced consistent with 200% or 300% annualized volatility stacking the odds against us. It was hard to comprehend for a newbie like me how such an option pricing was even mathematically possible. I did not really understand what the implied volatility priced into an option represents.

Today, I understand option mechanics much better and I believe I have identified a promising systematic trading strategy on these binary events. I have been using this as a little side hustle for a while and so far it seems to work. This strategy is actually surprisingly simple, but there are good reasons why it works anyway.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Fallacy Alarm
Publisher Terms
Substack
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share